LYR-210 AN INNOVATIVE THERAPEUTIC SOLUTION FOR CRS

Lyra’s lead product candidate, LYR-210, to treat chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses. LYR-210 is an anti-inflammatory implantable drug matrix based upon Lyra’s XTreo™ platform designed to elute mometasone furoate consistently and locally to the inflamed mucosal tissue of surgically-naïve CRS patients for up to six months from a single treatment. LYR-210 is being developed as an alternative to sinus surgery for CRS patients.

Learn MoreGET THE EXPERT PERSPECTIVE
LYR-210 in ENLIGHTEN Phase 3 Study
Randy OwRandall A. Ow, MD, FACS, FAAOA
Physician
Sacramento Ear, Nose & Throat

LYR-210’s unique properties address the challenges of CRS

Locally targeted
LYR-210 is delivered directly to the inflamed mucosal tissues, where its design optimizes surface area for local release and absorption of anti-inflammatory medication.
Anti-inflammatory
LYR-210 delivers mometasone furoate, a known potent anti-inflammatory agent. In its Phase 2 study, LYR-210 demonstrated rapid and durable improvements in symptom severity for most polyp and non-polyp patients.
Long acting
LYR-210 gradually releases mometasone furoate for over six months. Its flexible design conforms to the patient’s nasal anatomy and is designed to be unobtrusive to patients.
Accessible
LYR-210 is administered in an ENT office setting in a short procedure using a topical anesthetic and is designed to eliminate the need for other costly and more invasive CRS interventions.

HERE’S HOW LYR-210 WORKS

BEFORE LYR-210 TREATMENT

CRS patients experience at least two of the four cardinal symptoms (4CS) for more than 12 weeks, including nasal blockage, facial pain and pressure, nasal discharge, and decreased sense of smell. Persistent and severe symptoms cause sleep disturbances, daytime fatigue, depression, and anxiety, which significantly negatively impact quality of life for the CRS sufferer.

AFTER LYR-210 TREATMENT

Inflammation subsides as anti-inflammatory medicine is continually released directly to tissues. The mesh scaffold conforms to stay in place as inflammation recedes, offering up to six months of symptom improvement from a single treatment.

DESIGNED FOR IMPACT AT SITE OF CRS

LYR-210 enables long-acting therapy directly to the site of CRS inflammation, offering an alternative to address limitations of current CRS treatments

  • Topical nasal steroid sprays are not effective at reaching the site of inflammation deep within the nasal passages or maintaining a therapeutic concentration over time
  • Surgical interventions do not directly address underlying inflammation, lead to painful recovery, and often require additional surgery
© 2023 Lyra Therapeutics. All rights reserved.
Back to Top